Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.asjsur.2022.08.026 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
Int J Urol
October 2024
Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
Int J Urol
October 2024
Department of Urology, St. Marianna University School of Medicine, Kawasaki City, Kanagawa, Japan.
Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial.
Lancet Oncol
December 2022
Breast Oncology Program, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address:
Comment on dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: Results of the GETUG-AFU V05 VESPER trial.
Asian J Surg
February 2023
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, 610041, China. Electronic address:
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.
J Clin Oncol
September 2022
Shuxiong Zeng, MD, PhD, Zhensheng Zhang, MD, PhD, and Chuanliang Xu, MD, PhD, Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!